mgus package:survival R Documentation _M_o_n_o_c_l_o_n_a_l _g_a_m_m_a_p_o_t_h_y _d_a_t_a _D_e_s_c_r_i_p_t_i_o_n: Natural history of 241 subjects with monoclonal gammapothy of undetermined significance (MGUS). _U_s_a_g_e: mgus mgus1 mgus2 _F_o_r_m_a_t: mgus: A data frame with 241 observations on the following 12 variables. id: subject id age: age in years sex: 'male' or 'female' dxyr: year of diagnosis pcdx: for subjects who progress to a plasma cell malignancy the subtype of malignancy: multiple myeloma (MM) is the most common, followed by amyloidosis (AM), macroglobulinemia (MA), and other lymphprolifative (LP) pctime: days from MGUS until diagnosis of a plasma cell malignancy futime: days from diagnosis to last follow-up death: 1= follow-up is until death alb: albumin level at MGUS diagnosis creat: creatinine at MGUS diagnosis hgb: hemoglobin at MGUS diagnosis mspike: size of the monoclonal protien spike at diagnosis mgus1: The same data set in start,stop format. Contains the id, age, sex, and laboratory variable described above along with start, stop: sequential intervals of time for each subject status: =1 if the interval ends in an event event: the event type mgus2: The mgus data, but formatted in the competing risks style. Each subject has three observations, one for time to death, one for time to MM, and one for time to a PC malignancy other than MM. Contains the id, age, sex, and laboratory variable described above along with time: time to event or censoring status: 1 if the event occured, 0 otherwise event: death, myeloma, or other _D_e_t_a_i_l_s: Plasma cells are responsible for manufacturing immunoglobulins, an important part of the immune defense. At any given time there are estimated to be about 10^6 different immunoglobulins in the circulation at any one time. When a patient has a plasma cell malignancy the distribuion will become dominated by a single isotype, the product of the malignant clone, visible as a spike on a serum protein electrophoresis. Monoclonal gammapothy of undertermined significance (MGUS) is the presence of such a spike, but in a patient with no evidence of overt malignancy. This data set of 241 sequential subjects at Mayo Clinic was the groundbreaking study defining the natural history of such subjects. _S_o_u_r_c_e: Mayo Clinic data courtesy of Dr. Robert Kyle. _R_e_f_e_r_e_n_c_e_s: R Kyle, Benign monoclonal gammopathy - after 20 to 35 years of follow-up, Mayo Clinic Proc 1993; 68:26-36.